Efficacy and Safety of Armolipid Plus: An Updated PRISMA Compliant Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials.

Armolipid Plus is a multi-constituent nutraceutical that claims to improve lipid profiles. The aim of this PRISMA compliant systematic review and meta-analysis was to globally evaluate the efficacy and safety of Armolipid Plus on the basis of the available randomized, blinded, controlled clinical trials (RCTs). A systematic literature search in several databases was conducted in order to identify RCTs assessing the efficacy and safety of dietary supplementation with Armolipid Plus. Two review authors independently identified 12 eligible studies (1050 included subjects overall) and extracted data on study characteristics, methods, and outcomes. Meta-analysis of the data suggested that dietary supplementation with Armolipid Plus exerted a significant effect on body mass index (mean difference (MD) = -0.25 kg/m, = 0.008) and serum levels of total cholesterol (MD = -25.07 mg/dL, < 0.001), triglycerides (MD = -11.47 mg/dL, < 0.001), high-density lipoprotein cholesterol (MD = 1.84 mg/dL, < 0.001), low-density lipoprotein cholesterol (MD = -26.67 mg/dL, < 0.001), high sensitivity C reactive protein (hs-CRP, MD = -0.61 mg/L, = 0.022), and fasting glucose (MD = -3.52 mg/dL, < 0.001). Armolipid Plus was well tolerated. This meta-analysis demonstrates that dietary supplementation with Armolipid Plus is associated with clinically meaningful improvements in serum lipids, glucose, and hs-CRP. These changes are consistent with improved cardiometabolic health.